Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

PURPOSE: Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the glucocorticoid receptor, along with inhibition of translation of oncoprotein mRNAs. We studied selinexor in combination...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Vogl, Dan T., Dingli, David, Cornell, Robert Frank, Huff, Carol Ann, Jagannath, Sundar, Bhutani, Divaya, Zonder, Jeffrey, Baz, Rachid, Nooka, Ajay, Richter, Joshua, Cole, Craig, Vij, Ravi, Jakubowiak, Andrzej, Abonour, Rafat, Schiller, Gary, Parker, Terri L., Costa, Luciano J., Kaminetzky, David, Hoffman, James E., Yee, Andrew J., Chari, Ajai, Siegel, David, Fonseca, Rafael, Van Wier, Scott, Ahmann, Gregory, Lopez, Ilsel, Kauffman, Michael, Shacham, Sharon, Saint-Martin, Jean-Richard, Picklesimer, Carla D., Choe-Juliak, Cassandra, Stewart, A. Keith
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2018
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6905485/
https://ncbi.nlm.nih.gov/pubmed/29381435
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.75.5207
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires